- Updates on Chematur, Konspec and the Candy producer
- Lantmännen sparks hope for protein from feathers
- We keep our fair value of SEK 3.7 per share
Bioextrax reported an eventful Q4 2025, with EBIT of MSEK -5.0, slightly higher than expected. Cash at year-end amounted to MSEK 3.9, with MSEK 12.5 from the rights issue recorded as a recievable. The company is awaiting an agreement with Chematur regarding a PHBV facility in Asia, and has initiated a project with Lantmännen to trial protein from feathers in animal feed. Panel testing at the candy company has not yet started.
Read the full reporthere.
About Market Focus
The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.
This is a press release from Västra Hamnen Corporate Finance AB.
Web:vhcorp.se
Twitter: @vhcorp_se (https://x.com/vhcorp_se)